Introduction
Anthracycline-based regimens remain a standard firstline treatment for advanced breast cancer (ABC), but despite an objective tumor response rate of 50%-60% [1] , virtually all patients eventually develop progressive disease (PD). The efficacy of salvage chemotherapy is generally lower than that of first-line treatment [2] , and decreases with further chemotherapy treatments.
Taxanes have recently become available, and now represent the most active class of compounds and a standard treatment in patients unable to receive or having resistance to anthracyclines. Docetaxel has shown a high level of activity against ABC in second-and firstline chemotherapy [3] [4] [5] [6] [7] [8] . Of particular interest, it has shown similar response rates in both anthracyclinesensitive [3, 4, 6] and anthracycline-resistant patients [5, 7, 8] .
Cisplatin is also active in chemotherapy-naive ABC patients, with responses ranging from 45%-54% [9, 10] , being less active as a second or third-line treatment (6% mean response rate) [11, 12] .
Phase I studies have shown the combination of docetaxel and cisplatin (DC) active in different tumor types [13] , including untreated ABC [14, 15] . Based on these data, we have assessed the efficacy and tolerance of this combination in ABC patients with clinical resistance to anthracycline and/or mitoxantrone-based chemotherapy.
Patients and methods
From February 1996 to November 1997, 41 women with ABC entered this monocenter study. Eligibility criteria included histologically confirmed breast cancer, measurable metastatic disease, WHO performance status (PS) =£2, and life expectancy of at least three months. Patients had to have received at least one anthracycline-or mitoxantrone-based regimen, have an absolute granulocyte count ^ 1.5 x 10 9 /l; hemoglobin > 8 g/dl; a platelet count > 100 x 10 9 /l and age ^ 75 years. In addition, patients were classified according to their anthracycline-resistance, using the following version of Piccart et al.'s proposed classification [16] :
• Anthracycline refractory. PD as best response during anthracycline-based treatment (either adjuvant or palliative). • Anthracycline resistant: Response or initially stable disease (SD) during anthracycline-based treatment, then tumor progression, either within three months of completing anthracycline-based treatment for metastatic disease, or within six months of completing anthracycline-based adjuvant chemotherapy. Patients with symptomatic heart failure, severe arrhythmia, peripheral neuropathy, or active infection were ineligible. All patients gave their informed consent before accrual.
Pre-treatment evaluation included medical history and physical examination, differential blood cell count, standard biochemical profile, a CA 15-3 assay, chest X-ray, chest and abdomen CTscan, bone scan, and any other appropriate procedure. Blood and platelet counts were performed weekly during treatment. Clinical examination, biochemical tests, and CA 15-3 evaluations were performed every three weeks. Clinical and imaging source data were independently reviewed for anthracychne resistance, evaluability, and response assessment.
The initial q-3-week DC regimen given during a 24-hour hospitallsation consisted of docetaxel (Taxotere*. Laboratoires RhonePoulenc Rorer, Montrouge, France) on day one at 85 mg/m 2 , followed 6 hours later by cisplatin at 80 mg/m 2 with appropriate hydration. After the first two patients experienced severe hematological toxicity, the docetaxel dose was reduced to 75 mg/m 2 . Antiemetic treatment, consisting of granisetron 3 mg, and methylprednisolone 80 mg, was given by i.v infusion 10 minutes before the administration of either drug. Patients with severe neutropema had 20% dose reductions in subsequent cycles. No prophylactic G-CSF was given. Toxicity was assessed according to NC1-CTC criteria, and treatment was continued until disease progression, excessive toxicity or patient refusal.
Patients were evaluated for antitumor activity (WHO criteria) and time-related parameters. The duration of response was defined as the period from the first treatment course, to the first documentation of disease progression. Duration of response, time to disease progression (TTP) and overall survival (OS) were calculated using the KaplanMeier method. Total number with anthracycline-resistance a Total number anthracychne refractory a n (%)
41 (100) 32 (78) 8 (20) 1 (2) 26 (63) 15 (37) 21 (51) 16 (39) 17 (41) 29 (71) 18 (44) 30 (73) 11 (27) 15 (37) 15 (37) 38 (93) 5 (12) a See text for definition of terms
Results
Patient characteristics are shown in Table 1 . The majority of patients (78%) had a PS of 0. A total of 26 patients (63%) had received one prior chemotherapy regimen, while 15 (37%) had received 2 regimens; 34 had received adjuvant chemotherapy, 33 of them anthracycline-based. Twenty-one patients had received only anthracyclinecontaining adjuvant chemotherapy prior to study treatment, all of them relapsing either on treatment or within six months of its discontinuation. At baseline, 73% of patients had ^2 sites involved, and 71% had visceral involvement, with 39% having liver metastases. Three patients were classified as non-anthracycline-resistant because of PD at ten, fourteen and eighteen months after anthracycline-based therapy. Among the 38 anthracycline-resistant patients, 5 were anthracycline refractory.
Extent of exposure
A total of 223 chemotherapy cycles were administered, with a median number of 6 cycles per patient (range 1-8 cycles). In 15 patients, treatment was discontinued before the sixth course because of progression (7 patients, 17%) or disease stabilisation (8 patients, 20%). Two patients went off-study early for severe toxicity (one toxic death after the first cycle, and one reversible grade 2 renal toxicity after three cycles). There were treatment delays in seven patients (17%) in a total of eight cycles (4%), but no consecutive delays. Dose reductions of 20% were made for both docetaxel and cisplatin in two patients (5%) (both receiving 75 mg/m 2 docetaxel as initial dose) and seven cycles (3%). The mean cumulative doses given were 408 mg/m 2 for docetaxel, and 428 mg/m 2 for cisplatin.
Toxicity
Toxicity was evaluated using the NCI-CTC and is summarised in Table 3 . Myelosuppression was the main toxicity observed. Both patients treated with docetaxel at 85 mg/m 2 , who had also received radiotherapy covering 25% of their bone marrow, experienced grade 4 neutropenia at the first cycle, and one was hospitalised for febrile neutropenia. As a result of this hematological toxicity, the study continued with the docetaxel at 75 mg/m 2 . Grade 4 neutropenia, which was not cumulative and was usually only of a short duration (4-5 days), occurred in 27 patients (66%) and included febrile neutropenia in 10 patients (24%) and 12 cycles (5%). Four patients (10%) were hospitalised for febrile neutropenia. The median duration of hospitalisation was three days. One toxic death occurred due to neutropenic septic shock and pneumonia after two cycles with docetaxel at 75 mg/m 2 . This patient had multiple bulky pulmonary lesions at study entry. Grade 3 thrombocytopenia occurred in three patients (7%). Grade 2 anemia occurred in nine patients (22%).
Grade 3 and 4 vomiting occurred in one (2%) and two patients (5%), respectively. Four patients (10%) experienced grade 3 asthenia. Grade 3 fluid retention was observed in three patients (7%), one of whom dis- continued treatment after six cycles. Two patients (5%) experienced grade 3 mucositis. Five patients (12%) had grade 2 neurosensory toxicity, including three patients with peripheral neurotoxicity (7%) and two patients (5%) with grade 2 CDDP-induced auditive toxicity. No grade 3 peripheral sensory neuropathy was observed. One patient had grade 2 renal toxicity after three cycles, which was reversible after treatment discontinuation.
Response
Response to study treatment is summarised in Table 2 . Among the 38 anthracycline-resistant patients, 5 were not evaluable for response (1 early death from neutropenic septic shock, 1 patient with unevaluable hepatic lesions, and 3 patients who had no evaluable lesions, 2 having undergone excisional surgery of their evaluable disease before study entry).
Twelve of thirty-three anthracycline-resistant patients evaluable for efficacy experienced objective responses (ORR: 36%, 95% CI: 20%-55%), including two complete responses (CR). SD and PD were observed in 14 (42%) and 7 patients (21%), respectively. Of the 12 responding patients, 10 had visceral metastases including 8 with hepatic involvement, while 6 responders had failed anthracycline-based adjuvant treatment. In the three non-anthracycline-resistant patients, there were two partial responses. No responses were observed among the five anthracycline-refractory patients.
With a median follow-up of 101 weeks, the median duration of response was 29 weeks (range 18-70 weeks), the median TTP was 21 weeks (range 4-70 weeks) and median OS was 50 weeks (range 4-104+ weeks).
Discussion
This is the first report of the use of the DC regimen in anthracycline-resistant patients. Discrepancies between the preliminary results of this study [17] and the present one are due to a longer follow up and third-party data review. The same regimen has already been investigated in a phase I-II study for the first-line treatment of metastatic disease, with a response rate of 55% and a recommended dose (D/C = 100/75 mg/m 2 ) superior to that used in the present study [14] . The combination of cisplatin with the other available taxoid, paclitaxel, has also been studied [18] [19] [20] , giving a good safety profile, except in one study [19] where the prophylactic use of G-CSF was required and peripheral neuropathy was cumulative and doselimiting (52% of patients with grade ^2 versus 12% of grade 2 in the present study with the same median number of cycles). Response rates ranging from 48.5%-85% were reported in patients with metastatic breast cancer. However, 83% of the patients entered in these studies had not received prior chemotherapy for metastatic disease and, although some patients had been exposed to anthracyclines, most of them in the adjuvant setting, anthracycline-resistance was not reported. The published results of the paclitaxel-cisplatin combination cannot therefore be compared with the docetaxel combination in first-line patients [14] .
The ORR in the anthracycline-resistant patients (36%) in the present study falls between the 29% reported by Guastalla et al. [8] , and the studies by Valero et al. (51%) [7] and Ravdin et al. (50%) [5] . Of note, 83% of responders had visceral metastases, including 67% with hepatic involvement. The median response duration (29 weeks) and OS (50 weeks), from our study compare favourably with others, where duration of response was 23 and 24 weeks [7, 8] and OS 39 and 43 weeks, respectively [7, 8] . The median TTP (21 weeks) in the present study was similar to that found in other trials (20 and 17 weeks [5, 7] ). While the docetaxel dose of 85 mg/m 2 was judged too toxic after the first two patients, the 75 mg/m 2 dose resulted in fewer patients having grade 4 neutropenia (66%) than in other trials (93% and 88% [5, 7] ) with similar duration of neutropenia. rate of hospitalisation and morbidity. Grade 2-3 anemia was experienced by fewer patients (22%), compared with 68% found by Ravdin et al. [5] . The ad-hoc implementation of dose adjustments rather than the prophylactic prescription of granulocyte colony-stimulating factor (G-CSF) made the regimen feasible. The present regimen appears to be well tolerated, with only 7% and 10% of patients experiencing grade 2 and 3 asthenia, compared to 28% and 19%, respectively, reported by Ravdin et al. [5] . Interestingly, despite the potential neurotoxicity of both drugs, neurosensory toxicity was low, and fluid retention was also limited. This could be attributed to the fact that the median dose intensity and total cumulative dose of each drug were significantly lower than the dose administered in phase II studies of the single-agent regimens. Other docetaxel-based combination regimens, like docetaxel plus vinorelbine, may be interesting in anthracycline-resistant patients, although this combination does appear to be highly myelotoxic [21] [22] [23] [24] .
The DC regimen appears a good choice for first-line treatment of ABC, especially after anthracycline-based adjuvant treatment failure. Our results further indicate that this combination may be an interesting alternative to single agent docetaxel therapy in patients with anthracycline-resistant ABC, especially those at risk of hematological toxicity. The antitumor activity appears to be similar, especially in terms of TTP and OS. Although the most prevalent toxicity observed in the present study was grade 4 neutropenia, in 66% of patients and responsible for one death, it was of short duration and less prevalent than with single-agent docetaxel at the recommended dose of 100 mg/m 2 , while other toxicities, such as anemia, asthenia, and fluid retention appear lower than those encountered with single-agent docetaxel at the full recommended dose. Its eventual role in the treatment of metastatic breast cancer needs to be determined by controlled trials compared with docetaxel alone, and/or other second-line combinations.
